

2012. 03 – 2016. 02 Researcher, Department of Pharmaceutical Policy and Outcomes
Research, School of Pharmacy, Sungkyunkwan University

2009. 05 – 2012. 03 Researcher, Department of Health Technology Assessment,
National Evidence-based Healthcare Collaborating Agency (NECA)

2006. 11 – 2009. 05 Senior Researcher, Drug Information Research Institute
Sookmyung Women’s University

2004. 11 – 2006. 11 Pharmacist, Department of Pharmacy,
Hangang Sacred Heart Hospital

2003. 04 – 2004. 08 Pharmacist, Cho-II Pharmacy

2002. 07 – 2002. 08 Intern, Department of Pharmacy,
Catholic University of Korea St. Paul’s Hospital

LICENSURE AND CERTIFICATION

2003. 04 – Present Registered Pharmacist in South Korea

DISSERTATION

Doctor of philosophy, Health and Social Pharmacy

Estimation of Willingness to pay for a Quality-adjusted life year on a Cure (Adviser:
Eui-Kyung, Lee)

Master of Pharmacy, Clinical Pharmacy

Comparison analysis of main literature retrieval engine for Pharmacoeconomics: with
drugs used in nicotine dependence (Adviser: Eui-Kyung, Lee)

PEER-REVIEWD PUBLICATIONS

International Journals

1. **Song HJ**, Seo HJ, Lee Y. Kim SK. Effectiveness of high-intensity laser therapy in the treatment of musculoskeletal disorders: a systematic review and meta-analysis of randomized controlled trials. *Medicine*. 2018. (In press)
2. **Song HJ**, Lee EK. Evaluation of willingness to pay per quality-adjusted life year for a cure: a contingent valuation method using a scenario-based survey. *Medicine* (Baltimore). 2018;97(38):e12453.

3. Hong SH, Lee JY, Park SK, Nam JH, **Song HJ**, Park SY, Lee EK. The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea. *Clin Drug Investig.* 2018;38(8):727-736.
4. **Song HJ**, Park S, Kwon JW. Quality of life of middle-aged adults in single households in South Korea. *Qual Life Res.* 2018;27(8):2117-2125.
5. **Song HJ**, Hwang J, Pi S, Ahn S, Heo Y, Park S, Kwon JW. The impact of obesity and overweight on medical expenditures and disease incidence in Korea from 2002 to 2013. *PLoS One.* 2018;10(13(5):e0197057. *(Co-first author)*
6. Kang HR, **Song HJ**, Nam JH, Hong SH, Yang SY, Ju S, Lee SW, Kim TB, Kim HL, Lee EK. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. *BMJ Open.* 2018;22;8(3):e020825.
7. Song HS, Shin JS, Lee J, Lee YJ, Kim MR, Cho JH, Kim KW, Park Y, **Song HJ**, Park SY, Kim S, Kim M, Ha IH. Association between temporomandibular disorders, chronic diseases, and ophthalmologic and otolaryngologic disorders in Korean adults: A cross-sectional study. *PLoS One.* 2018;31;13(1):e0191336.
8. Lee YJ, Kwon SH, Hong SH, Nam JH, **Song HJ**, Lee JS, Lee EK, Shin JY. Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database. *Clin Ther.* 2017;39(3):527-536.
9. **Song HJ**, Seo HJ, Son H. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. *Eur J Clin Pharmacol.* 2016;72(11):1289-301.
10. Shin SO, Seo HJ, Park H, **Song HJ**. Effects of mulberry leaf extract on blood glucose and serum lipid profiles in patients with type 2 diabetes mellitus: A systematic review. *Eur J Integr Med.* 2016;8:602-8.
11. Kim DK, **Song HJ**, Lee EK, Kwon JW. Effect of sex and age on the association between suicidal behavior and obesity in Korean adult: A cross-sectional nationwide study. *BMJ Open.* 2016;6(6):e010183. *(Co-first author)*
12. Kim HL, Kim D, Jang EJ, Lee MY, **Song HJ**, Park SY, Cho SK, Sung YK, Choi CB, Won S, Bang SY, Cha HS, Choe JY, Chung WT, Hong SJ, Jun JB, Kim J, Kim SK, Kim

TH, Kim TJ, Koh E, Lee H, Lee HS, Lee J, Lee SS, Lee SW, Park SH, Shim SC, Yoo DH, Yoon BY, Bae SC, Lee EK. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. *Rheumatol Int.* 2016;36(4):505-13.

13. **Song HJ**, Lee EK, Kwon JW. Gender Differences in the Impact of Obesity on Health-Related Quality of Life. *Asia Pac J Public Health.* 2016;28(2):146-56
14. Kim GM, Woo JM, Jung SY, Shin S, **Song HJ**, Park J, Ahn J. Positive association between serious psychiatric outcomes and complications of diabetes mellitus in patients with depressive disorders. *Int J Psychiatry Med.* 2015;50(2):131-46.
15. Lee SP, Jang EJ, Kim YJ, Cha MJ, Park SY, **Song HJ**, Choi JE, Shim JI, Ahn J, Lee HJ. Cost-effectiveness of coronary CT angiography in patients with chest pain: Comparison with myocardial single photon emission tomography. *J Cardiovasc Comput Tomogr.* 2015;9(5):428-37.
16. **Song HJ**, Lee JA, Han E, Lee EK. Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis. *Tumour Biol.* 2015;36(9):6773-9.
17. **Song HJ**, Son H, Seo HJ, Lee H, Choi SM, Lee S. Effect of self-administered foot reflexology for symptom management in healthy persons: a systematic review and meta-analysis. *Complement Ther Med.* 2015;23(1):79-89. *(Co-first author)*
18. **Song HJ**, Seo HJ, Lee H, Son H, Choi SM, Lee S. Effect of self-acupressure for symptom management: a systematic review. *Complement Ther Med.* 2015;23(1):68-78.
19. **Song HJ**, Choi SM, Seo HJ, Lee H, Son H, Lee S. Self-administered foot reflexology for the management of chronic health conditions: a systematic review. *J Altern Complement Med.* 2015;21(2):69-76. *(Co-first author)*
20. Lee YJ, **Song HJ**, Heo Y, Oh SH, Kwon JW, Moon KH, Park JM, Lee SK. Validation of the Korean version Moorehead-Ardelt quality of life questionnaire II. *Ann Surg Treat Res.* 2014;87(5):265-72. *(Co-first author)*
21. **Song HJ**, Lee EK, Lee JA, Kim HL, Jang KW. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov

- model analysis. *Tumour Biol.* 2014;35(9):8771-9.
22. **Song HJ**, Kwon JW, Kim YJ, Oh SH, Heo Y, Han SM. Bariatric surgery for the treatment of severely obese patients in South Korea-is it cost effective? *Obes Surg.* 2013;23(12):2058-67. *(Co-first author)*
 23. **Song HJ**, Kwon JW, Kim N, Park YS. Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. *Gut Liver.* 2013;7(2):182-9. *(Co-first author)*
 24. Oh SH, **Song HJ**, Kwon JW, Park DJ, Lee YJ, Chun H, Kim S, Shim KW. The improvement of quality of life in patients treated with bariatric surgery in Korea. *J Korean Surg Soc.* 2013;84(3):131-9. *(Co-first author)*
 25. Suh HS, **Song HJ**, Choi JE, Jang EJ, Son HJ, Lee SM, Kim JS, Choi D. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: A systematic review and meta-analysis. *Int J Technol Assess Health Care.* 2011;27(1):11-22.

Submitted:

26. **Song HJ**, Park H, Park S, Kwon JW. The association between proton pump inhibitor use and the risk of tuberculosis: a case-control study. Submitted to *Pharmacoepidemiology and Drug Safety* 2018. [Under review]
27. **Song HJ**, Park H, Seo HJ. The association between proton pump inhibitor use and risk for tuberculosis: a systematic review. Submitted to *International Journal of Tuberculosis and Lung Disease* 2018. [Under review]
28. Son HJ, **Song HJ**, Seo HJ, Lee H, Choi SM, Lee S. Is self-administered coffee enema safe and effective: a systematic review. Submitted to *BMC Complementary and Alternative Medicine* 2018. *(Co-first author)* [Under review]

Developing:

29. **Song HJ**, Seo HJ, Lee Y. Effectiveness of high-intensity laser therapy in the treatment of patients with knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.
30. **Song HJ**, Park HM, Park SY, Ha SY, Lee EK, Park SY, Bae EJ, Ku H. Estimation of quality of life based on the response to treatment in atopic dermatitis: a population-based survey.

Korean Journals

31. Kang JK, Kim MS, Jang WI, Seo YS, Kim HJ, Cho CK, Yoo HJ, Paik EK, Cha YJ, **Song HJ**. The clinical utilization of radiation therapy in Korea between 2009 and 2013. *Radiat Oncol J*. 2016;34(2):88-95.
32. Suh HS, **Song HJ**, Jang EJ, Kim JS, Choi D, Lee SM. Use of drug-eluting stents versus bare-metal stents in Korea: a cost-minimization analysis using population data. *J Prev Med Public Health*. 2013;46(4):201-9.
33. Kim Y, Park J, Jung YJ, Kim JM, Lee T, Bae E, **Song HJ**, Shin S. Issues for Costing Method of Caregiving in Healthcare. *J Health Technol Assess*. 2015;2(2):93-98.
34. Shin S, Park JY, **Song HJ**, Kim Y, Jung Y, Lee TJ, Bae E. Review for Cost estimation for Cost of illness and Economic Evaluation in Korea. *Korean J Health Econ Policy*. 2013;19(1):77-92.
35. Kang SH, **Song HJ**, Heo JH, Lee EK. Pharmacoeconomic Analysis of Tafluprost compared with Latanoprost on the Treatment of Primary open Angle Glaucoma or Ocular Hypertension in Korea. *Kor J Clin Pharm*. 2010;20(3):278-87.
36. Kim Y, Shin S, Park SY, **Song HJ**, Park JY, Bae E, Ahn J. A study of identifying factors affecting cost-effectiveness threshold calculation in Korea. *The Korean J Health Econ Policy* 2010;16(2):79-100.
37. Kho MJ, Hong SH, Oh YB. Lee YJ, **Song HJ**, Lee EK. Analysis of Master's and Doctoral Theses on Social Pharmacy Field in Korea. *Kor J Clin Pharm*. 2009;53(4):173-78.
38. Lee EK, Noh ES, Yeom CS, **Song HJ**, Kim IS. Policy Directions to Improve Consumer Welfare by Comparative Analysis of Drug Distribution Focused on the Survey Analysis of Direct vs Wholesale Distribution. *J Consumer Policy Studies* 2008;33(1):123-48.
39. **Song HJ**, Lee YS, Lee EK. Comparison of Literature Retrieval Engines for Pharmacoeconomic Evaluation Research of Bupropione or Varenicline Therapy for Smoking Cessation. *Kor J Clin Pharm*. 2007;17(2):87-95.

POSTER PRESENTATIONS

1. **Song HJ**, Park HY, Park JW, Sohn HS, Kwon JW. Association between proton pump inhibitors use and dementia incidence in elderly people. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Canada, Montreal. August 2017.
2. **Song HJ**, Lee EK. Estimation of willingness to pay for a quality-adjusted life year on a cure. ISPOR 7th Asia-Pacific conferences. Singapore. September 2016.
3. Han E, **Song HJ**, Lee EK. Evaluating willingness-to-pay for reversal of rocuronium-induced neuromuscular blockade using sugammadex: A double-blinded dichotomous choice. Singapore. January 2014.
4. **Song HJ**, Han E, Kang SH, Lee EK. Evaluating Willingness-to-Pay Threshold for Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Contingent Valuation Survey. ISPOR 16th Annual European Congresses. Dublin, Ireland. November 2013.
5. Lee HJ, **Song HJ**, Lee EK. Enzalutamide, Cabazitaxel, and Abiraterone for overall survival of patients with prostate cancer after docetaxel treatment: an indirect comparison analysis. 2013 Fall International Convention of the Pharmaceutical Society of Korea. South Korea, Osong. October 2013.
6. Rhu SJ, **Song HJ**, Lee EK. Comparison of Utility Weights using VAS and TTO methods for residual muscle relaxation effects. 2013 Fall Korean Association of Health Technology Assessment conference. South Korea, Seoul. October 2013.
Awarded Best Poster Presentation Award.
7. **Song HJ**, Jung YJ, Park JY, Park SY, Shin S. Safety and efficacy of sublingual immunotherapy: comprehensive meta-analysis of randomized controlled trials. 9th HTAi annual meeting. Spain, Bilbao. June 2012.
8. **Song HJ**, Park JY, Park SY, Jung YJ, Shin S. Systematic reviews of subcutaneous immunotherapy for allergic rhinitis and/or asthma. 9th HTAi annual meeting. Spain, Bilbao. June 2012.
9. **Song HJ**, Park SY, Jung YJ, Park JY, Shin S. Sublingual versus subcutaneous immunotherapy for rhinitis and/or asthma: A systematic review. 9th HTAi annual meeting. Spain, Bilbao. June 2012.

10. Oh SH, **Song HJ**, Lee HJ, Lee JY, Choi JE, Kwon JY. The improvement of quality of life in patients treated with bariatric surgery. ISPOR 17th Annual International Meeting. USA, Washington. June 2012.
11. Kwon JW, **Song HJ**, Lee HJ, Lee JY, Choi JE, Oh SH. Cost-utility of bariatric surgery for the treatment of obese patients in South Korea. ISPOR 17th Annual International Meeting. USA, Washington. June 2012.
12. **Song HJ**, Lee HJ, Lee JY, Choi JE, Oh SH, Kwon JW. Clinical and cost effectiveness of bariatric surgery for obese patients: economic evaluation in South Korea. ISPOR 17th Annual International Meeting. USA, Washington. June 2012.
13. Jung SY, Shin S, **Song HJ**, Park J. Ahn J. Relationship between adherence to antidepressant treatments and depressive relapse. ISPOR 16th Annual International Meeting. USA, Baltimore. May 2011.
14. Jung SY, Shin S, **Song HJ**, Park JY, Ahn J. Impact of adherence to first therapy on the risk of antidepressant switching. ISPOR 16th Annual International Meeting. USA, Baltimore. May 2011.
15. Shin S, Jung SY, **Song HJ**, Park JY, Ahn J. Cost-effectiveness of antidepressant in Korea. ISPOR 16th Annual International Meeting. USA, Baltimore. May 2011.
16. Kim Y, Shin S, Park SY, **Song HJ**, Park JY, Bae E, Ahn J. How Much For a QALY In Korea. ISPOR 16th Annual International Meeting. USA, Baltimore. May 2011.
17. Kang MH, **Song HJ**, Park SY, Kang SH, Ko SK, Lee EK. Long-Term Cost-Effectiveness of Sirolimus Regimen Compared with Calcineurin Inhibitor Regimens for Immunosuppression after Renal Transplantation in Korea. ISPOR 13th Annual European Congress. Czech Republic, Prague. November 2010.
18. **Song HJ**, Kim Y, Shin S, Park SY, Park JY, Bae E, Ahn J. An Analysis of Incremental Effectiveness Range for Economic Evaluation in Korea. 2010 HTAi Annual Meeting. Dublin, Ireland. June 2010.
19. Kim Y, Shin S, Park SY, **Song HJ**, Park JY, Bae E, Ahn J. Looking for a cost-effectiveness threshold in Korea. 2010 HTAi Annual Meeting. Dublin, Ireland. June 2010.
20. Suh HS, **Song HJ**, Jang E, Lee SM, Choi J, Kim JS, Choi DH. Drug-eluting stents versus bare-metal stents for acute myocardial infarction: An economic analysis

- approach. ISPOR 15th Annual International meeting. USA, Atlanta. May 2010.
21. Suh HS, **Song HJ**, Choi J, Jang E, Son HJ, Kim JS, Choi DH, Lee SM. Comparative effectiveness review: drug-eluting stents versus bare-metal stents for acute myocardial infarction. ISPOR 15th Annual International meeting. USA, Atlanta. May 2010.
 22. Choi J, Jang E, Suh HS, Choi DH, **Song HJ**, Lee SM, Kim JS. Anti-platelet agent use and patterns of healthcare utilization in patients with acute myocardial infarction (AMI) using Korea National Health Insurance claims database. ISPOR 15th Annual International meeting. USA, Atlanta. May 2010. *Awarded Final Poster Award.*
 23. Jung SY, **Song HJ**, Shin S, Shin E, Park JY, Ahn J. Factors associated with adherence and persistency to antidepressants in Korea. International Society for Pharmacoepidemiology (ISPE) 2010 Meeting. April 2010.
 24. Shu HS, **Song HJ**, Choi J, Jang E, Son HJ, Kim JS, Choi DH, Lee SM. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: A systematic review. 2010 Korean Cardiology-Related Societies Joint Scientific Session. South Korea, Pusan. April 2010.
 25. **Song HJ**, Kang SH, Heo JH, Lee EK. Cost-effectiveness Analysis of Tafluprost Compared with Latanoprost on the Treatment of Primary Open Angle Glaucoma in South Korea. ISPOR 12th Annual European Congress. France, Paris. October 2009.
 26. Bae J, **Song HJ**, Lee EK. Comparison of effectiveness between the pharmacotherapies for the Smoking cessation: varenicline, bupropion and nicotine replacement therapy. ISPOR 3rd Asia-Pacific Conference. South Korea, Seoul. September 2008.
 27. Park SY, **Song HJ**, Lee JH, Heo JH, Lee EK. Cost effectiveness analysis of nilotinib compared with dasatinib and high dose imatinib on the treatment of chronic myeloid leukemia. ISPOR 3rd Asia-Pacific Conference. South Korea, Seoul. September 2008.
 28. Bae JY, **Song HJ**, Joe KH, Kim CH, Song HR, Ryu GC, Kim DJ, Lee EK. A long term Cost-Effectiveness analysis model for smoking cessation in Korea. ISPOR 13th Annual International Meeting. Canada, Toronto. May 2008.
 29. **Song HJ**, Lee EK. Comparative analysis of main literature retrieval engine for pharmacoeconomics. 2007 Fall International Convention of the Pharmaceutical

Society of Korea. South Korea, Seoul. November 2007.

30. Noh ES, Yeom CS, **Song HJ**, Lee EK. Competitiveness comparison between pharmaceutical wholesalers and drug companies in Korea. 2007 Spring International Convention of the Pharmaceutical Society of Korea. South Korea, Gwangju. May 2007.
31. Noh ES, Yeom CS, **Song HJ**, Lee EK. Trend analysis of pharmaceutical E-Commerce. 2007 Spring International Convention of the Pharmaceutical Society of Korea. South Korea, Gwangju. May 2007.

BOOKS

NECA Research Method Series 4. Costing methods in Healthcare. National Evidence-based Healthcare Collaborating Agency. 2012

GRANTS AND CONTRACTS

2018. 09 – Present Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Funding source: NIH/NIDA (K01DA045618), USA
Role: Participating researcher
2018. 09 – Present Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations: A Pilot Study
Funding source: UF college of Pharmacy PROSPER Research Enhancement Award, USA
Role: Participating researcher
2018. 08 – Present Improving medication adherence with telehealthcare medication therapy management to change health outcomes in adolescents and young adults with asthma (MATCH)
Funding source: NIH/NHLBI (1 R01 HL136945), USA
Role: Participating researcher
2018. 09 – 2019. 01 Statistical analysis for the health-related quality of life of hypothetical health status in atopic dermatitis
Funding source: NDnex Inc.

- Role:* Principal Investigator
2018. 08 – Present Cost-effectiveness of primary prophylaxis versus on-demand treatment in children with haemophilia
Funding source: Department of Health, South Africa
Role: Participating researcher
2018. 07 – 2018. 09 Indirect treatment comparison between tegoprazan and proton pump inhibitors for the treatment of non-erosive reflux disease
Funding source: NDnex Inc.
Role: Principal Investigator
2018. 04 – 2019. 03 Effectiveness and safety of high-intensity laser therapy in the treatment of musculoskeletal disorders: A systematic review and meta-analysis
Funding source: Chosun University
Role: Project coordinator
2017. 09 – 2018. 08 Prescription pattern for proton pump inhibitor (PPI) and association between adverse events such as dementia and chronic kidney disease and PPI use in South Korea
Funding source: Business and Research Foundation,
SungKyunKwan University
Role: Principal Investigator
2017. 10 – 2018. 01 Systematic review of pembrolizumab for locally advanced or metastatic urothelial carcinoma, relapsed or refractory classical Hodgkin lymphoma, and recurrent and/or metastatic head and neck squamous cell carcinoma.
Funding source: NDnex Inc.
Role: Principal Investigator
2017. 01 – 2017. 08 Cost-effectiveness of ixazomib for relapse or refractory multiple myeloma patients
Funding source: Takeda Pharmaceuticals Korea Co., Ltd.
Role: Project coordinator
2016. 11 – 2017. 05 Local adaptation of economic model for ixazomib in combination with lenalidomide and dexamethasone for relapse or refractory multiple

- myeloma patients
Funding source: Takeda Pharmaceuticals Korea Co., Ltd.
Role: Principal Investigator
2016. 09 – 2016. 12 Cost-effectiveness of vedolizumab in patients with crohn’s disease
Funding source: Takeda Pharmaceuticals Korea Co., Ltd.
Role: Project coordinator
2016. 09 – 2016. 12 Cost-effectiveness of vedolizumab in patients with Ulcerative Colitis
Funding source: Takeda Pharmaceuticals Korea Co., Ltd.
Role: Project coordinator
2016. 08 – 2018. 12 Korean Medicine Clinical Practice Guideline Adaption and Clinical Trials for temporomandibular disorders
Funding source: Korea Health Industry Development Institute
Role: Consultant
2016. 07 – 2017. 08 Cost-effectiveness of bendamustine in patients with Non-Hodgkin’s lymphoma.
Funding source: Eisai Korea Inc.
Role: Project coordinator
2016. 07 – 2017. 03 Clinical utilization of radiation therapy in South Korea
Funding source: Korea Institute of Radiological and Medical Sciences
Role: Data analyst
2016. 06 – 2018. 12 Korean Medicine Clinical Practice Guideline Adaption and Clinical Trials for Neck pain
Funding source: Korea Health Industry Development Institute
Role: Consultant
2016. 05 – 2017. 08 The Clinical usefulness and Cost-effectiveness of bariatric surgery Versus drug intervention in patients severely obese patients
Funding source: Korea Health Industry Development Institute
Role: Participating researcher
2016. 05 – 2017. 08 Comparative effectiveness researches for treatment, diagnosis, and monitoring in asthma using a multi-center cohort
Funding source: Korea Health Industry Development Institute

- Role:* Participating researcher
2016. 02 – 2016. 12 Multi-Criteria Decision Analysis for immune oncology therapy:
A case of Pembrolizumab
Funding source: Merck Sharp & Dohme Korea Co., Ltd.
Role: Project coordinator
2016. 02 – 2017. 09 Cost-effectiveness of selexipag in pulmonary arterial hypertension
Funding source: Actelion Ltd.
Role: Principal investigator
2016. 02 – 2017. 09 Indirect Comparison between selexipag and iloprost or treprostinil
in pulmonary arterial hypertension
Funding source: Actelion Ltd.
Role: Principal investigator
2016. 01 – 2016. 12 Cost-effectiveness of nivolumab in non-squamous cell and squamous
cell lung cancer
Funding source: Ono Pharmaceutical Co., Ltd.
Role: Participating researcher
2015. 09 – 2016. 04 Cost-effectiveness of mepolizumab in refractory eosinophilic asthma
Funding source: GlaxoSmithKline Korea, Inc.
Role: Project coordinator
2015. 06 – 2016. 02 Estimation of Willingness to pay on a cure
Funding source: Gilead Sciences, Inc
Role: Project coordinator
2014. 05 – 2015. 05 Cost-effectiveness of omalizumab in severe persistent allergic asthma
Funding source: Novartis Korea, Inc.
Role: Project coordinator
2013. 11 – 2014. 07 Cost-effectiveness of first-line liposomal doxorubicin (Myocet™)
in breast cancer
Funding source: Teva Handok, Inc.
Role: Project coordinator
2013. 11 – 2014. 07 Indirect Comparison between liposomal doxorubicin plus
cyclophosphamide and conventional doxorubicin plus docetaxel

- in breast cancer
Funding source: Teva Handok, Inc.
Role: Project coordinator
2012. 12 – 2013. 12 Indirect treatment comparison between enzalutamide and cabazitaxel or abiraterone for the treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel
Funding source: Astellas Pharma Korea, Inc.
Role: Project coordinator
2012. 12 – 2013. 09 Cost-effectiveness of enzalutamide in the treatment of patients with metastatic castration-resistant prostate cancer previously treated with docetaxel
Funding source: Astellas Pharma Korea, Inc.
Role: Project coordinator
2012. 08 – 2012. 12 Evaluating Willingness to pay threshold for sugammadex reversal of rocuronium-induced neuromuscular blockade: A Contingent valuation survey
Funding source: Merck Sharp & Dohme Korea Co., Ltd.
Role: Project coordinator
2012. 04 – 2012. 11 Safety and efficacy of self-administered non-drug Complementary and alternative medicine (CAM) treatment: A systematic review
Funding source: Korea Institute of Oriental Medicine (KIOM)
Role: Project coordinator
2012. 01 - 2012. 09 Cost-effectiveness of mifamurtide in children and adolescent with high-grade, resectable, non-metastatic osteosarcoma
Funding source: Takeda Pharmaceuticals Korea Co., Ltd.
Role: Project coordinator
2011. 04 – 2011. 12 The Clinical usefulness and Cost-effectiveness of CT Coronary Angiography for the diagnosis of Ischemic heart disease in patients with chest pain
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher

2011. 03 – 2011. 12 The Clinical effectiveness and economic analysis of bariatric surgery for severe obesity
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Project coordinator
2011. 03 – 2011. 12 Comparative clinical effectiveness for sublingual versus subcutaneous immunotherapy for allergic rhinitis and asthma
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Project coordinator
2011. 02 -2011. 12 Costing method in Health care
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher
2010. 06 – 2010. 12 Clinical effectiveness and factor analysis of barriers for hearing aids in patients with hearing difficulty and loss
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher
2009. 12 – 2010. 08 The Clinical usefulness and cost-effectiveness for other drugs of digestive system
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher
2009. 05 – 2011. 03 The factors of affecting medication adherence and cost-effectiveness analysis of antidepressants
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher
2009. 05 – 2010. 06 Use of Economic evaluation on the Healthcare Decision-Making Process: A Study on the threshold of Cost-effectiveness
Funding source: National Evidence-based Collaborating Agency (NECA)
Role: Participating researcher
2009. 07 – 2009. 12 The Clinical efficacy and Cost-effectiveness of drug-eluting stents (DES) versus bare-metal stent (BMS) in patients with acute myocardial infarction
Funding source: National Evidence-based Collaborating Agency (NECA)

- Role:* Participating researcher
2008. 08 – 2009. 06 Cost-effectiveness of tafluprost in patients with glaucoma or ocular hypertension
Funding source: Santen Pharmaceutical Co., Ltd
Role: Project coordinator
2008. 02 – 2008. 08 Cost-effectiveness of sirolimus in patients with renal transplant
Funding source: Wyeth, Inc.
Role: Project coordinator
2007. 09 – 2008. 02 Cost-effectiveness of nilotinib in imatinib-resistant Chronic myeloid leukemia
Funding source: Novartis Korea, Inc.
Role: Participating researcher
2007. 02 – 2007. 09 Cost-effectiveness of smoking cessation treatment
Funding source: Pfizer Ltd.
Role: Project coordinator
2006. 10 – 2007. 03 Policy measures to ensure transparency and advancement of drug distribution
Funding source: Ministry of Health and Welfare (MOHW)
Role: Participating researcher

TEACHING EXPERIENCE

2017. 03 - 2017. 06 Biostatistics in healthcare
Catholic University of Korea
2017. 03 - 2017. 06 Introduction to pharmacoeconomics
CHA University
2016. 11 Introduction and application of decision analytic model
in cost-effectiveness analysis using TreeAge
Sungkyunkwan University
2016. 07 Markov modeling and sensitivity analysis using TreeAge
National Evidence-based Collaborating Agency (NECA)
2016. 06 - 2017. 04 Introduction to pharmacoeconomics and budget impact analysis

Santen Pharmaceutical Korea, Co., Ltd.

2016. 04 Introduction and application of systematic review
Handok, Inc.

2015. 11 Utilization of economic evaluation research in nursing science
Chosun University

2015. 09 – 2015.12 Markov modeling in hepatocellular carcinoma
Korea Health Industry Development Institute

2015. 05 Markov modeling using TreeAge
CHA University

2015. 05 Modeling with decision analytic tree using TreeAge
CHA University

2015. 05 Heterogeneity and publication bias in meta-analysis
Sungkyunkwan University

2015. 03 Application of pharmacoeconomic study: cost-effectiveness of
mifamurtide in patient with osteosarcoma
Sungkyunkwan University

2015. 03 Database searching method in systematic review
Sungkyunkwan University

2015. 03 Application of systematic review and meta-analysis using Review
Manager and STATA: Drug-eluting stents versus bare-metal stents
in acute myocardial infarction
Sungkyunkwan University

2013. 03 Modeling good research practices
ISPOR Korea Regional Chapter

2012. 10 Application of cost-benefit study: Willingness to pay per QALY
in Herpes Zoster
Sungkyunkwan University

2015. 05 Basic and advanced Markov modeling using TreeAge
National Evidence-based Collaborating Agency (NECA)

2012. 06 Application of validation of health utility index: Taiwan Version of
the Moorehead-Ardelt Quality of Life Questionnaire II

SungKyunKwan University

2012. 06 Methods for measuring and estimating costs in economic evaluation
Consortium for HRD Ability Magnified Program (CHAMP)

2012. 06 Utility estimates of health status in cost-utility analysis
Consortium for HRD Ability Magnified Program (CHAMP)

2012. 06 Application of systematic review and meta-analysis: Drug-eluting
stents versus bare-metal stents in acute myocardial infarction
Sungkyunkwan University

2012. 05 Database searching method in systematic review
Sungkyunkwan University

2012. 03 Analyzing and managing the increase of drug costs
Sungkyunkwan University

2011. 11 Health survey methods: questionnaire design
National Evidence-based Collaborating Agency (NECA)

2010. 03 Analyzing and undertaking meta-analysis
National Evidence-based Collaborating Agency (NECA)

2010. 03 WinBUGS software: introduction, setup, and basic analysis
National Evidence-based Collaborating Agency (NECA)

2009. 12 Community and international studies in designing clinical research
National Evidence-based Collaborating Agency (NECA)

2009. 09 Precision and accuracy in designing clinical research
National Evidence-based Collaborating Agency (NECA)

2009. 09 Decision analytic model in cost-effectiveness analysis
National Evidence-based Collaborating Agency (NECA)

2009. 07 Costing methods in cost-effectiveness analysis
National Evidence-based Collaborating Agency (NECA)

2009. 07 Application of pharmacoeconomic study: cost-effectiveness of sirolimus
in renal transplant
National Evidence-based Collaborating Agency (NECA)

AWARDS AND SCHOLARSHIPS

2017. 08 Post-Doctoral Program International Institution located outside Korea.
Business and Research Foundation, SungKyunKwan University.
Suwon, South Korea.
2013. 11 Best Poster Presentation Award
2013 Fall Korean Association of Health Technology Assessment conference.
Seoul, South Korea.
2013. 09 BK21 PLUS Scholarship Program for Leading Universities and Students
Center for Global Creativity in Pharmaceutical Education and Research,
SungKyunKwan University. Suwon, South Korea.
2010. 05 Final Poster Award
ISPOR 15th Annual International meeting. Atlanta, USA.

PROFESSIONAL ORGANIZATIONS

- 2011 – Present ISPOR Korea Regional Chapter
- 2011 – Present Korean Academy of Social and Managed Care Pharmacy (KASMCP)
- 2010 – 2012 Health Technology Assessment International (HTAi)
- 2009 – Present The Korean Association of Health Economics and Policy (KAHEP)
- 2008 – Present Korean Society for Pharmacoepidemiology and Risk Management
(KSPRM)
- 2007 – Present International Society for Pharmacoeconomics and Outcomes Research
(ISPOR)
- 2007 – Present The Pharmaceutical Society of Korea (PSK)
- 2007 – Present Korean Association of Health Technology Assessment (KATHA)

PEER REVIEW ACTIVITIES

- BMC Complementary and Alternative Medicine (BCAM)
- Journal of Medical Economics (JME)
- Value in Health Regional Issues (ViHRI)
- International Journal of Technology Assessment in Health Care (IJTAHC)

PROFESSIONAL SKILLS

Data Analysis and Statistical Software

SAS

STATA

SPSS

Decision Analytic Modeling

TreeAge Pro Healthcare

Microsoft Excel (Microsoft Office Specialist Certifications for version 2002)

Meta-Analysis Software

Review Manager (RevMan)

STATA

Comprehensive Meta-Analysis (CMA)